The optimization method for synthesis of technetium-99m-luteolin as radiotracer in the development of cancer drugs from flavonoid

Danni Ramdhani; Maula Eka Sriyani; S Fairuz Nabila

doi:10.4103/japtr.JAPTR_161_19

The optimization method for synthesis of technetium-99m-luteolin as radiotracer in the development of cancer drugs from flavonoid

J Adv Pharm Technol Res. 2020 Apr-Jun;11(2):59-63. doi: 10.4103/japtr.JAPTR_161_19. Epub 2020 Apr 22.

Authors

Danni Ramdhani¹, Maula Eka Sriyani², S Fairuz Nabila¹

Affiliations

¹ Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Padjadjaran University, Sumedang, West Java, Indonesia.
² Applied Nuclear Science and Technology Center (PSTNT), National Atomic Energy Agency (BATAN), Bandung, West Java, Indonesia.

Abstract

The aim of this study is to find the optimum conditions of labeling luteolin flavonoid compounds with technetium-99m (^99mTc) to meet the purity requirements stated in the United States Pharmacopeia. This compound is expected to be a potential radiotracer compound for diagnosing cancer. The optimization method in labeling luteolin with technetium determines the parameters such as pH, SnCl₂.2H₂O, genistein concentration, and incubation time. Optimization results of Technetium-99m-luteolin labeling obtained optimum pH conditions 8, the amount of SnCl₂.2H₂O as a reducing agent 60 μL, the optimum amount of luteolin 6 mg/ml, and the optimum incubation time is 30 min. This optimum condition obtained a ^99mTc-Luteolin radiochemical purity yield of 94.15%. The radiochemical purity percentage of the ^99mTc-Luteolin compound has fulfilled the requirements listed at United States Pharmacopeia, which is ≥90%.

Keywords: Luteolin; radiochemical purity; radiotracer; technetium-99m; technetium-99m-genistein.